Search hospitals > South Carolina > Greenville

Greenville Cancer Treatment Center

Claim this profile
Greenville, South Carolina 29605
Global Leader in Cancer
Global Leader in Leukemia
Conducts research for Tumors
Conducts research for Lymphoblastic Leukemia-Lymphoma
Conducts research for Lymphoma
163 reported clinical trials
4 medical researchers
Photo of Greenville Cancer Treatment Center in GreenvillePhoto of Greenville Cancer Treatment Center in GreenvillePhoto of Greenville Cancer Treatment Center in Greenville

Summary

Greenville Cancer Treatment Center is a medical facility located in Greenville, South Carolina. This center is recognized for care of Cancer, Leukemia, Tumors, Lymphoblastic Leukemia-Lymphoma, Lymphoma and other specialties. Greenville Cancer Treatment Center is involved with conducting 163 clinical trials across 303 conditions. There are 4 research doctors associated with this hospital, such as Ki Chung, MD, Tarek M. Sabagh, Jhansi L. Koduri, and W. Jeff Edenfield, MD.

Area of expertise

1Cancer
Global Leader
Greenville Cancer Treatment Center has run 40 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive
2Leukemia
Global Leader
Greenville Cancer Treatment Center has run 30 trials for Leukemia. Some of their research focus areas include:
Stage II
Stage I
CD7 positive

Top PIs

Clinical Trials running at Greenville Cancer Treatment Center

Breast Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Colon Cancer
Colorectal Cancer
Renal Cell Carcinoma
Recurrence
Bile Duct Cancer
Image of trial facility.

Radiation and HER2-Targeted Therapy

for Breast Cancer

This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Image of trial facility.

Hormone Therapy with or without Radiation

for Breast Cancer

This study is evaluating whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Greenville Cancer Treatment Center?
Greenville Cancer Treatment Center is a medical facility located in Greenville, South Carolina. This center is recognized for care of Cancer, Leukemia, Tumors, Lymphoblastic Leukemia-Lymphoma, Lymphoma and other specialties. Greenville Cancer Treatment Center is involved with conducting 163 clinical trials across 303 conditions. There are 4 research doctors associated with this hospital, such as Ki Chung, MD, Tarek M. Sabagh, Jhansi L. Koduri, and W. Jeff Edenfield, MD.